WallStreetZenWallStreetZen

NYSE: RMD
Resmed Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Resmed earnings were $1.3B for the trailing 12 months ending Mar 31, 2025, with 37.1% growth year over year. The latest RMD earnings report on Mar 31, 2025 announced Q1 2025 earnings of $365.0M, up 5.9% from last quarter. For the last reported fiscal year 2024 ending Jun 30, 2024, RMD reported annual earnings of $1.0B, with 13.7% growth. The next RMD earnings date is Jul 31, 2025.

RMD past earnings growth

How has RMD's earnings growth performed historically?

Company
37.12%
Industry
16.42%
Market
34.13%
RMD's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
RMD's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
RMD's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

RMD earnings history

Current Revenue
$5.0B
Current Earnings
$1.3B
Current Profit Margin
26.2%
RMD's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

RMD Return on Equity

Current Company
25.2%
Current Industry
9.7%
Current Market
31.3%
RMD's Return on Equity (25.2%)... subscribe to Premium to read more.
High Return on Equity Performance

RMD undefined

Current Company
18.2%
Current Industry
7.9%
RMD is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when RMD announces earnings.

RMD undefined

Current Company
23.92%
Current Industry
10.3%
RMD has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

RMD vs Medical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
RMD$1.80B$1.31B+20.22%$8.94
ALC$2.63B$1.12B+111.98%$2.26
BDX$4.65B$1.50B+8.79%$5.18
WST$744.00M$467.20M+12.64%$6.42
BAX$637.00M-$560.00MN/A-$1.10
View Top Medical Stocks

RMD earnings dates

Next earnings date
Jul 31, 2025

Resmed Earnings Reports & History FAQ

What were Resmed's earnings last quarter?

On RMD's earnings call on Invalid Date, Resmed (NYSE: RMD) reported Q1 2025 earnings per share (EPS) of $2.49, up 22.06% year over year. Total RMD earnings for the quarter were $365.04 million. In the same quarter last year, Resmed's earnings per share (EPS) was $2.04.

If you're new to stock investing, here's how to buy Resmed stock.

When does Resmed report earnings?

The next RMD earnings call is Invalid Date. Add RMD to your watchlist to be reminded of Resmed's next earnings date.

Is Resmed profitable or losing money?

As of the last Resmed earnings report, Resmed is currently profitable. Resmed's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $1.31 billion, a 37.03% increase year over year.

What was RMD's earnings growth in the past year?

As of Resmed's earnings date in Invalid Date, Resmed's earnings has grown 37.12% year over year. This is 20.7 percentage points higher than the US Medical Instruments & Supplies industry earnings growth rate of 16.42%. RMD earnings in the past year totalled $1.31 billion.

What are Resmed's earnings expectations?

The current EPS estimate for Resmed's earnings report in Invalid Date is $2.48.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.